What is AngioDynamics' operating income?

AngioDynamics' total operating income in 2026 was -$39.93 million, based on the following breakdown: Total Gross Profit: $174.89 million Total Operating Expenses: $214.82 million

AngioDynamics (ANGO) Financials

$13.59 +0.15 (+1.12%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$13.59 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Compare

Annual Income Statements for AngioDynamics

This table shows AngioDynamics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	5/31/2016	5/31/2017	5/31/2018	5/31/2019	5/31/2020	5/31/2021	5/31/2022	5/31/2023	5/31/2024	5/31/2025	5/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-44	5.01	16	61	-167	-32	-27	-52	-184	-34	-37
Consolidated Net Income / (Loss)	-44	5.01	16	61	-167	-32	-27	-52	-184	-34	-37
Net Income / (Loss) Continuing Operations	-44	-7.05	-6.23	-11	-167	-32	-27	-52	-184	-34	-37
Total Pre-Tax Income	-3.25	-14	-17	-15	-168	-36	-30	-54	-192	-34	-36
Total Operating Income	1.02	-11	-14	-9.40	-167	-35	-28	-51	-192	-40	-40
Total Gross Profit	174	144	144	156	150	157	166	174	155	158	175
Total Revenue	354	270	262	271	264	291	316	339	304	292	320
Operating Revenue	354	270	262	271	264	291	316	339	304	292	320
Total Cost of Revenue	180	126	118	115	114	134	150	165	149	135	145
Operating Cost of Revenue	180	126	118	115	114	134	150	165	149	135	145
Total Operating Expenses	173	155	158	165	317	192	194	225	347	198	215
Selling, General & Admin Expense	31	31	31	35	38	36	38	40	41	42	44
Marketing Expense	84	75	73	77	79	81	95	104	103	103	113
Research & Development Expense	25	24	24	28	30	36	31	30	32	26	29
Amortization Expense	18	15	14	17	18	18	19	19	13	10	11
Other Operating Expenses / (Income)	3.36	-17	0.25	-6.78	-12	0.09	1.21	2.32	0.43	0.27	0.00
Impairment Charge	-	-	0.00	0.00	159	0.00	0.00	15	159	0.00	0.00
Restructuring Charge	13	28	15	15	6.01	20	9.04	16	53	16	18
Other Special Charges / (Income)	-	-	-	-	-	-	0.00	0.00	-54	0.00	0.00
Total Other Income / (Expense), net	-4.27	-3.12	-3.09	-5.31	-1.04	-0.77	-1.48	-3.26	0.80	5.92	3.63
Interest & Investment Income	-	-	-	-	-	-	-	-2.70	1.61	0.98	-0.30
Other Income / (Expense), net	-0.89	-0.28	-0.03	-0.21	-0.13	0.09	-0.79	-0.55	-0.82	4.94	3.93
Income Tax Expense	40	-7.24	-11	-3.56	-1.35	-4.50	-3.40	-2.00	-7.29	-0.04	0.44
Basic Earnings per Share	($1.21)	$0.14	$0.44	$1.64	($4.39)	($0.82)	($0.68)	($1.33)	($4.59)	($0.83)	($0.88)
Weighted Average Basic Shares Outstanding	36.16M	36.62M	37.07M	37.48M	37.96M	38.34M	39.01M	39.48M	40.18M	40.85M	41.53M
Diluted Earnings per Share	($1.21)	$0.14	$0.44	$1.64	($4.39)	($0.82)	($0.68)	($1.33)	($4.59)	($0.83)	($0.88)
Weighted Average Diluted Shares Outstanding	36.16M	36.62M	37.07M	37.48M	37.96M	38.34M	39.01M	39.48M	40.18M	40.85M	41.53M
Weighted Average Basic & Diluted Shares Outstanding	36.44M	35.80M	37.10M	37.40M	37.87M	38.44M	38.97M	39.67M	40.28M	40.63M	41.33M

This table shows AngioDynamics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	Q4 2026
Period end date	11/30/2023	2/29/2024	5/31/2024	8/31/2024	11/30/2024	2/28/2025	5/31/2025	8/31/2025	11/30/2025	2/28/2026	5/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-29	-188	-13	-13	-11	-4.41	-6.05	-11	-6.35	-8.08	-11
Consolidated Net Income / (Loss)	-29	-188	-13	-13	-11	-4.41	-6.05	-11	-6.35	-8.08	-11
Net Income / (Loss) Continuing Operations	-29	-188	-13	-13	-11	-4.41	-6.05	-11	-6.35	-8.08	-11
Total Pre-Tax Income	-13	-200	-14	-13	-11	-4.41	-6.11	-11	-6.36	-8.07	-11
Total Operating Income	-13	-200	-14	-13	-11	-9.97	-5.79	-11	-6.13	-13	-10
Total Gross Profit	40	36	39	37	40	39	42	42	45	41	47
Total Revenue	79	75	71	67	73	72	80	76	79	78	87
Operating Revenue	79	75	71	67	73	72	80	76	79	78	87
Total Cost of Revenue	39	39	32	31	33	33	38	34	35	37	40
Operating Cost of Revenue	39	39	32	31	33	33	38	34	35	37	40
Total Operating Expenses	53	236	53	50	51	49	48	53	51	54	57
Selling, General & Admin Expense	9.29	11	10	11	10	10	10	13	10	11	10
Marketing Expense	25	25	25	26	26	26	26	28	27	27	31
Research & Development Expense	8.66	8.19	6.72	6.29	6.43	6.91	6.59	6.42	7.77	7.08	8.18
Amortization Expense	3.56	3.29	2.57	2.57	2.56	2.60	2.59	2.65	2.64	2.67	2.72
Restructuring Charge	6.19	35	8.42	4.31	5.87	3.29	2.16	2.76	3.64	6.52	4.68
Total Other Income / (Expense), net	0.50	0.16	0.31	0.43	0.25	5.57	-0.32	-0.18	-0.23	4.88	-0.84
Interest & Investment Income	0.53	0.39	-	0.61	0.23	0.14	0.00	-0.00	-0.10	-0.09	-0.11
Other Income / (Expense), net	-0.03	-0.24	-0.26	-0.17	0.01	5.43	-0.33	-0.18	-0.13	4.97	-0.74
Income Tax Expense	16	-12	-0.69	0.13	-0.11	-0.00	-0.06	0.07	-0.01	0.01	0.37
Basic Earnings per Share	($0.72)	($4.67)	($0.35)	($0.31)	($0.26)	($0.11)	($0.15)	($0.26)	($0.15)	($0.19)	($0.28)
Weighted Average Basic Shares Outstanding	40.22M	40.23M	40.18M	40.65M	40.92M	40.85M	40.85M	41.17M	41.54M	41.60M	41.53M
Diluted Earnings per Share	($0.72)	($4.67)	($0.35)	($0.31)	($0.26)	($0.11)	($0.15)	($0.26)	($0.15)	($0.19)	($0.28)
Weighted Average Diluted Shares Outstanding	40.22M	40.23M	40.18M	40.65M	40.92M	40.85M	40.85M	41.17M	41.54M	41.60M	41.53M
Weighted Average Basic & Diluted Shares Outstanding	39.86M	40.05M	40.28M	40.63M	40.47M	40.61M	40.63M	41.20M	41.22M	41.32M	41.33M

This table details how cash moves in and out of AngioDynamics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	5/31/2016	5/31/2017	5/31/2018	5/31/2019	5/31/2020	5/31/2021	5/31/2022	5/31/2023	5/31/2024	5/31/2025	5/31/2026
Net Change in Cash & Equivalents	14	15	27	154	-173	-6.27	-19	16	31	-20	-2.03
Net Cash From Operating Activities	45	56	41	37	-15	24	-7.19	0.08	-28	-10	3.09
Net Cash From Continuing Operating Activities	45	56	41	37	-15	24	-7.19	0.08	-28	-10	3.09
Net Income / (Loss) Continuing Operations	-44	5.01	16	61	-167	-32	-27	-52	-184	-34	-37
Consolidated Net Income / (Loss)	-44	5.01	16	61	-167	-32	-27	-52	-184	-34	-37
Depreciation Expense	28	25	23	26	24	26	29	31	28	26	23
Non-Cash Adjustments To Reconcile Net Income	6.90	12	8.03	-39	170	25	14	29	122	13	19
Changes in Operating Assets and Liabilities, net	54	14	-6.24	-11	-42	4.36	-24	-7.02	6.89	-15	-2.52
Net Cash From Investing Activities	-7.57	-2.55	-3.66	83	-63	-14	-19	-9.75	124	-10	-5.95
Net Cash From Continuing Investing Activities	-7.57	-2.55	-3.66	83	-63	-14	-19	-9.75	124	-10	-5.95
Purchase of Property, Plant & Equipment	-2.33	-3.00	-2.39	-3.12	-7.24	-5.19	-4.30	-3.81	-2.52	-4.46	-2.58
Acquisitions	-3.27	0.00	-1.27	-85	-56	0.00	-3.60	-0.54	-3.25	0.00	0.00
Divestitures	-	0.00	0.00	169	-	-	0.00	0.00	135	0.00	0.00
Other Investing Activities, net	-2.00	-	-	0.00	0.00	-8.52	-11	-5.39	-5.02	-5.71	-3.37
Net Cash From Financing Activities	-24	-38	-12	34	-95	-17	7.68	25	-64	-0.26	0.56
Net Cash From Continuing Financing Activities	-24	-38	-12	34	-95	-17	7.68	25	-64	-0.26	0.56
Repayment of Debt	-16	-142	-5.00	-15	-133	-20	0.00	-46	-50	-0.68	0.00
Repurchase of Common Equity	0.00	-14	-	-	-	-	-	0.00	0.00	-1.67	0.00
Issuance of Debt	0.00	116	0.00	55	40	0.00	5.00	70	0.00	6.31	0.00
Other Financing Activities, net	-9.85	-9.85	-6.55	-6.07	-1.97	3.01	2.68	1.17	-14	-4.22	0.56
Effect of Exchange Rate Changes	-0.04	0.00	0.47	-0.38	-	0.33	-0.52	0.04	0.13	0.40	0.27
Cash Interest Paid	3.06	2.97	3.19	5.12	0.41	0.73	0.56	2.58	0.00	0.19	0.43
Cash Income Taxes Paid	0.33	-0.10	0.04	0.43	0.68	0.31	0.33	0.34	0.46	0.80	0.41

This table details how cash moves in and out of AngioDynamics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	Q4 2026
Period end date	11/30/2023	2/29/2024	5/31/2024	8/31/2024	11/30/2024	2/28/2025	5/31/2025	8/31/2025	11/30/2025	2/28/2026	5/31/2026
Net Change in Cash & Equivalents	3.31	18	-2.40	-21	-0.92	-9.33	11	-17	2.88	-3.83	16
Net Cash From Operating Activities	5.27	-13	5.00	-18	2.47	-13	19	-16	4.66	-3.11	17
Net Cash From Continuing Operating Activities	5.27	-13	5.00	-18	2.47	-13	19	-16	4.66	-3.11	17
Net Income / (Loss) Continuing Operations	-29	-188	-13	-13	-11	-4.41	-6.05	-11	-6.35	-8.08	-11
Consolidated Net Income / (Loss)	-29	-188	-13	-13	-11	-4.41	-6.05	-11	-6.35	-8.08	-11
Depreciation Expense	6.69	7.52	6.82	6.79	6.86	6.32	5.83	6.02	5.75	5.59	5.60
Non-Cash Adjustments To Reconcile Net Income	3.25	161	2.30	4.19	3.34	3.15	2.22	5.26	3.75	3.78	6.60
Changes in Operating Assets and Liabilities, net	24	6.72	9.33	-16	3.01	-18	17	-16	1.51	-4.39	17
Net Cash From Investing Activities	-1.79	29	-2.34	-2.41	-1.96	-3.19	-2.62	-1.55	-1.62	-1.51	-1.27
Net Cash From Continuing Investing Activities	-1.79	29	-2.34	-2.41	-1.96	-3.19	-2.62	-1.55	-1.62	-1.51	-1.27
Purchase of Property, Plant & Equipment	-1.79	-1.85	2.68	-2.41	-1.96	-3.19	3.09	-1.55	-1.62	-1.51	2.10
Net Cash From Financing Activities	-0.35	0.69	-5.00	-0.51	-1.12	7.15	-5.77	0.14	-0.09	0.62	-0.11
Net Cash From Continuing Financing Activities	-0.35	0.69	-5.00	-0.51	-1.12	7.15	-5.77	0.14	-0.09	0.62	-0.11
Other Financing Activities, net	-	-	-4.25	0.00	-	-0.06	-4.16	-0.09	-0.09	-0.10	0.84
Effect of Exchange Rate Changes	0.19	-0.02	-0.06	0.12	-0.31	-0.13	0.72	0.19	-0.07	0.17	-0.02

This table presents AngioDynamics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	5/31/2016	5/31/2017	5/31/2018	5/31/2019	5/31/2020	5/31/2021	5/31/2022	5/31/2023	5/31/2024	5/31/2025	5/31/2026
Total Assets	726	708	705	836	594	561	553	533	318	280	267
Total Current Assets	146	154	168	315	153	141	143	164	193	168	163
Cash & Equivalents	32	48	74	228	54	48	29	45	76	56	54
Accounts Receivable	53	45	39	44	31	35	52	53	44	43	48
Inventories, net	55	55	39	40	60	49	51	55	61	62	52
Prepaid Expenses	3.24	6.13	4.30	4.00	7.31	8.70	11	4.62	13	7.54	8.77
Plant, Property, & Equipment, net	48	45	26	24	28	37	45	44	36	32	27
Total Noncurrent Assets	532	509	512	497	413	383	364	325	89	80	77
Intangible Assets	167	146	113	145	197	169	152	111	77	69	67
Other Noncurrent Operating Assets	3.83	1.89	3.42	3.84	15	13	11	11	11	10	9.46
Total Liabilities & Shareholders' Equity	726	708	705	836	594	561	553	533	318	280	267
Total Liabilities	219	193	163	222	139	122	128	154	112	97	96
Total Current Liabilities	67	72	57	73	51	58	74	84	91	76	75
Accounts Payable	16	18	16	23	19	20	28	40	38	33	32
Accrued Expenses	22	39	34	38	29	35	35	27	41	36	39
Other Current Liabilities	-	-	-	0.00	2.13	2.50	2.65	2.00	7.58	7.39	4.30
Total Noncurrent Liabilities	152	121	106	148	88	64	54	71	21	21	22
Noncurrent Deferred & Payable Income Tax Liabilities	22	26	17	15	24	20	16	13	4.85	4.07	5.32
Other Noncurrent Operating Liabilities	26	3.99	1.78	9.37	64	24	13	7.89	16	17	16
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	507	515	543	615	455	439	424	378	206	183	171
Total Preferred & Common Equity	507	515	543	615	455	439	424	378	206	183	171
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	507	515	543	615	455	439	424	378	206	183	171
Common Stock	526	533	544	555	562	574	587	600	611	622	636
Retained Earnings	-16	-11	5.13	66	-100	-132	-158	-211	-395	-429	-466
Treasury Stock	-2.10	-5.71	-5.71	-5.71	-5.71	-5.71	-5.71	-5.71	-5.71	-7.38	-7.38
Accumulated Other Comprehensive Income / (Loss)	-0.79	-1.32	-0.95	-1.35	-1.34	3.15	1.36	-4.72	-4.37	-2.02	7.68

This table presents AngioDynamics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	11/30/2022	2/28/2023	8/31/2023	11/30/2023	2/29/2024	8/31/2024	11/30/2024	2/28/2025	8/31/2025	11/30/2025	2/28/2026
Total Assets	558	543	494	500	325	294	292	285	266	270	261
Total Current Assets	159	153	175	185	197	173	175	172	157	161	156
Cash & Equivalents	30	30	58	61	78	55	54	45	39	42	38
Accounts Receivable	53	51	50	52	49	40	43	43	43	44	46
Inventories, net	63	64	60	64	58	65	66	63	62	66	59
Prepaid Expenses	13	8.04	8.16	8.72	11	13	12	15	13	9.71	14
Plant, Property, & Equipment, net	46	46	43	43	37	34	33	33	31	31	29
Total Noncurrent Assets	353	345	275	272	91	87	83	81	78	78	76
Intangible Assets	142	134	107	104	82	76	73	71	68	67	65
Other Noncurrent Operating Assets	11	11	9.43	8.48	9.33	11	10	9.68	9.54	11	10
Total Liabilities & Shareholders' Equity	558	543	494	500	325	294	292	285	266	270	261
Total Liabilities	150	145	66	98	106	97	105	100	87	93	87
Total Current Liabilities	74	70	57	78	86	77	89	78	68	72	66
Accounts Payable	35	36	25	38	35	31	35	30	32	35	29
Accrued Expenses	27	22	26	29	31	34	40	37	28	30	32
Other Current Liabilities	2.59	2.38	1.84	1.76	10	6.52	8.97	5.76	8.74	6.72	4.66
Total Noncurrent Liabilities	77	76	8.69	20	20	20	16	22	19	21	21
Noncurrent Deferred & Payable Income Tax Liabilities	14	13	1.28	18	5.92	4.63	4.33	4.20	4.27	4.33	4.55
Other Noncurrent Operating Liabilities	13	12	7.41	2.60	14	16	12	17	14	17	17
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	408	398	428	401	219	197	187	186	179	176	173
Total Preferred & Common Equity	408	398	428	401	219	197	187	186	179	176	173
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	408	398	428	401	219	197	187	186	179	176	173
Common Stock	594	597	604	606	609	614	617	620	626	629	633
Retained Earnings	-180	-189	-165	-194	-382	-408	-419	-423	-440	-446	-455
Treasury Stock	-5.71	-5.71	-5.71	-5.71	-5.71	-6.27	-7.38	-7.38	-7.38	-7.38	-7.38
Accumulated Other Comprehensive Income / (Loss)	-0.29	-3.85	-5.65	-4.71	-2.81	-3.27	-3.75	-3.53	0.06	1.00	2.71

This table displays calculated financial ratios and metrics derived from AngioDynamics' official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	5/31/2016	5/31/2017	5/31/2018	5/31/2019	5/31/2020	5/31/2021	5/31/2022	5/31/2023	5/31/2024	5/31/2025	5/31/2026
DEI Shares Outstanding	36,367,049.00	36,780,397.00	36,804,506.00	37,215,894.00	37,694,757.00	38,137,367.00	-	-	-	40,606,986.00	41,318,915.00
DEI Adjusted Shares Outstanding	36,367,049.00	36,780,397.00	36,804,506.00	37,215,894.00	37,694,757.00	38,137,367.00	-	-	-	40,606,986.00	41,318,915.00
DEI Earnings Per Adjusted Shares Outstanding	-1.20	0.14	0.44	1.65	-4.42	-0.83	-	-	-	-0.84	-0.89
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-0.74%	-23.77%	-3.01%	3.43%	-2.39%	10.17%	8.66%	7.13%	-10.28%	-3.76%	9.46%
EBITDA Growth	13.34%	-52.72%	-32.89%	81.62%	-981.14%	93.53%	100.95%	-23,806.82%	-693.50%	94.44%	-41.65%
EBIT Growth	102.67%	-8,778.79%	-23.96%	32.38%	-1,641.41%	78.96%	16.85%	-76.81%	-273.54%	81.88%	-2.83%
NOPAT Growth	129.52%	-1,197.74%	-26.80%	33.69%	-1,678.40%	78.88%	19.31%	-79.77%	-275.99%	79.24%	0.07%
Net Income Growth	-1,186.60%	111.49%	226.18%	275.51%	-371.91%	81.08%	15.85%	-97.54%	-251.53%	81.56%	-8.09%
EPS Growth	-1,244.44%	111.57%	214.29%	272.73%	-367.68%	81.32%	17.07%	-95.59%	-245.11%	81.92%	-6.02%
Operating Cash Flow Growth	76.04%	23.29%	-25.94%	-9.32%	-138.87%	265.54%	-129.86%	101.08%	-36,200.00%	64.03%	130.50%
Free Cash Flow Firm Growth	161.09%	-60.00%	353.19%	-173.52%	106.16%	-734.24%	-9.68%	218.62%	75.96%	-126.15%	14.21%
Invested Capital Growth	-9.80%	-5.68%	-22.85%	18.64%	-23.38%	2.50%	4.41%	-18.86%	-61.47%	-5.35%	-7.96%
Revenue Q/Q Growth	0.84%	-24.25%	-0.52%	31.93%	-4.64%	6.79%	3.32%	1.22%	-6.20%	3.24%	2.06%
EBITDA Q/Q Growth	-8.56%	-71.75%	266.73%	302.50%	-968.34%	93.59%	100.57%	-229.89%	3.22%	45.25%	-63.22%
EBIT Q/Q Growth	-94.76%	-152.09%	51.24%	70.87%	-2,056.39%	79.34%	32.98%	-38.67%	3.14%	19.71%	-15.45%
NOPAT Q/Q Growth	-37.47%	73.75%	51.72%	71.20%	-2,112.34%	79.28%	34.79%	-39.30%	3.21%	17.82%	-12.41%
Net Income Q/Q Growth	-2,908.28%	119.91%	1,137.50%	1,242.53%	-439.32%	81.35%	33.21%	-40.82%	4.17%	17.88%	-17.06%
EPS Q/Q Growth	-3,933.33%	119.72%	1,366.67%	1,161.54%	-432.58%	81.57%	33.98%	-41.49%	4.18%	19.42%	-17.33%
Operating Cash Flow Q/Q Growth	22.47%	0.81%	13.09%	3.43%	-321.25%	52.74%	-102.36%	101.07%	-63.66%	57.69%	-30.55%
Free Cash Flow Firm Q/Q Growth	-41.11%	106.14%	2,256.34%	8.80%	-88.67%	-171.06%	-23.25%	303.99%	-42.53%	31.61%	-24.70%
Invested Capital Q/Q Growth	223.24%	-3.42%	-23.57%	-19.69%	-32.96%	-4.45%	-0.31%	-18.44%	-10.34%	-13.03%	-13.71%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	49.26%	53.36%	54.98%	57.64%	56.89%	53.88%	52.41%	51.44%	50.90%	53.92%	54.62%
EBITDA Margin	7.98%	4.95%	3.43%	6.01%	-54.29%	-3.19%	0.03%	-6.16%	-54.47%	-3.15%	-4.07%
Operating Margin	0.29%	-4.14%	-5.42%	-3.47%	-63.26%	-12.12%	-9.00%	-15.11%	-63.32%	-13.66%	-12.47%
EBIT Margin	0.04%	-4.25%	-5.43%	-3.55%	-63.31%	-12.09%	-9.25%	-15.27%	-63.59%	-11.97%	-11.24%
Profit (Net Income) Margin	-12.32%	1.86%	6.24%	22.67%	-63.14%	-10.84%	-8.40%	-15.48%	-60.66%	-11.62%	-11.48%
Tax Burden Percent	1,339.99%	-35.03%	-94.62%	-417.22%	99.20%	87.51%	88.64%	96.34%	96.20%	99.89%	101.22%
Interest Burden Percent	-2,464.39%	124.78%	121.56%	153.10%	100.54%	102.45%	102.35%	105.22%	99.16%	97.21%	100.83%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.11%	-1.33%	-1.96%	-1.36%	-25.29%	-6.08%	-4.74%	-9.21%	-55.81%	-21.40%	-22.91%
ROIC Less NNEP Spread (ROIC-NNEP)	-38.92%	15.05%	-121.39%	-72.02%	43.57%	10.68%	52.30%	124.30%	42.32%	-11.93%	-6.88%
Return on Net Nonoperating Assets (RNNOA)	-8.40%	2.31%	5.05%	11.96%	-5.89%	-0.98%	-1.40%	-3.85%	-7.33%	3.91%	2.14%
Return on Equity (ROE)	-8.28%	0.98%	3.09%	10.60%	-31.18%	-7.06%	-6.15%	-13.07%	-63.15%	-17.50%	-20.77%
Cash Return on Invested Capital (CROIC)	10.42%	4.52%	23.84%	-18.41%	1.18%	-8.55%	-9.06%	11.61%	32.93%	-15.91%	-14.61%
Operating Return on Assets (OROA)	0.02%	-1.60%	-2.01%	-1.25%	-23.38%	-6.09%	-5.25%	-9.53%	-45.45%	-11.71%	-13.16%
Return on Assets (ROA)	-5.81%	0.70%	2.31%	7.96%	-23.32%	-5.46%	-4.77%	-9.66%	-43.36%	-11.37%	-13.43%
Return on Common Equity (ROCE)	-8.28%	0.98%	3.09%	10.60%	-31.18%	-7.06%	-6.15%	-13.07%	-63.15%	-17.50%	-20.77%
Return on Equity Simple (ROE_SIMPLE)	-8.59%	0.97%	3.01%	9.98%	-36.67%	-7.18%	-6.25%	-13.86%	-89.67%	-18.58%	0.00%
Net Operating Profit after Tax (NOPAT)	0.71	-7.82	-9.92	-6.58	-117	-25	-20	-36	-135	-28	-28
NOPAT Margin	0.20%	-2.90%	-3.79%	-2.43%	-44.28%	-8.49%	-6.30%	-10.58%	-44.32%	-9.56%	-8.73%
Net Nonoperating Expense Percent (NNEP)	39.03%	-16.38%	119.43%	70.66%	-68.86%	-16.76%	-57.04%	-133.51%	-98.13%	-9.47%	-16.02%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	-15.29%	-16.36%
Cost of Revenue to Revenue	50.74%	46.64%	45.02%	42.36%	43.11%	46.12%	47.59%	48.56%	49.10%	46.08%	45.38%
SG&A Expenses to Revenue	8.64%	11.54%	11.84%	12.90%	14.34%	12.34%	12.16%	11.81%	13.54%	14.39%	13.65%
R&D to Revenue	7.08%	8.95%	9.30%	10.44%	11.24%	12.50%	9.72%	8.82%	10.37%	8.96%	9.20%
Operating Expenses to Revenue	48.97%	57.51%	60.39%	61.11%	120.14%	66.00%	61.41%	66.55%	114.22%	67.58%	67.09%
Earnings before Interest and Taxes (EBIT)	0.13	-11	-14	-9.60	-167	-35	-29	-52	-193	-35	-36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	28	13	8.96	16	-143	-9.28	0.09	-21	-166	-9.21	-13
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.86	1.08	1.43	1.14	0.85	2.01	1.79	0.98	1.23	2.26	2.78
Price to Tangible Book Value (P/TBV)	0.00	68.48	5.37	5.74	6.73	12.75	10.71	3.44	1.97	3.64	4.58
Price to Revenue (P/Rev)	1.23	2.06	2.96	2.58	1.46	3.03	2.41	1.10	0.83	1.42	1.48
Price to Earnings (P/E)	0.00	110.75	47.38	11.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.90%	2.11%	8.77%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.88	1.07	1.79	1.16	0.83	2.08	1.78	1.12	1.35	2.82	3.60
Enterprise Value to Revenue (EV/Rev)	1.52	2.27	3.03	2.25	1.25	2.93	2.42	1.15	0.60	1.23	1.31
Enterprise Value to EBITDA (EV/EBITDA)	18.98	45.81	88.41	37.36	0.00	0.00	8,706.95	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	4,062.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	752.52	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	11.86	10.98	19.19	16.24	0.00	35.43	0.00	5,014.56	0.00	0.00	136.12
Enterprise Value to Free Cash Flow (EV/FCFF)	8.04	22.94	6.56	0.00	60.51	0.00	0.00	8.66	2.28	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.26	0.21	0.17	0.22	0.00	0.05	0.08	0.17	0.02	0.00	0.00
Long-Term Debt to Equity	0.21	0.18	0.16	0.20	0.00	0.05	0.06	0.13	0.00	0.00	0.00
Financial Leverage	0.22	0.15	-0.04	-0.17	-0.14	-0.09	-0.03	-0.03	-0.17	-0.33	-0.31
Leverage Ratio	1.42	1.40	1.34	1.33	1.34	1.29	1.29	1.35	1.46	1.54	1.55
Compound Leverage Factor	-35.11	1.75	1.62	2.04	1.34	1.32	1.32	1.42	1.44	1.50	1.56
Debt to Total Capital	20.83%	17.06%	14.73%	18.17%	0.18%	4.35%	7.37%	14.58%	2.25%	0.00%	0.00%
Short-Term Debt to Total Capital	4.55%	2.36%	1.12%	1.62%	0.18%	0.00%	1.92%	3.33%	2.25%	0.00%	0.00%
Long-Term Debt to Total Capital	16.28%	14.71%	13.61%	16.56%	0.00%	4.35%	5.46%	11.25%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	79.17%	82.94%	85.27%	81.83%	99.82%	95.65%	92.63%	85.42%	97.75%	100.00%	100.00%
Debt to EBITDA	4.72	7.93	10.46	8.39	-0.01	-2.16	383.90	-3.10	-0.03	0.00	0.00
Net Debt to EBITDA	3.52	4.28	2.04	-5.60	0.37	3.04	56.34	-0.96	0.43	0.00	0.00
Long-Term Debt to EBITDA	3.69	6.84	9.67	7.64	0.00	-2.16	284.09	-2.39	0.00	0.00	0.00
Debt to NOPAT	187.29	-13.54	-9.45	-20.76	-0.01	-0.81	-1.70	-1.80	-0.04	0.00	0.00
Net Debt to NOPAT	139.59	-7.31	-1.85	13.85	0.46	1.14	-0.25	-0.56	0.53	0.00	0.00
Long-Term Debt to NOPAT	146.35	-11.67	-8.73	-18.91	0.00	-0.81	-1.25	-1.39	0.00	0.00	0.00
Altman Z-Score	1.79	2.17	3.35	2.64	1.14	4.50	3.71	1.38	-1.05	1.44	1.66
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.19	2.15	2.93	4.30	2.97	2.45	1.93	1.95	2.12	2.21	2.19
Quick Ratio	1.30	1.30	2.00	3.70	1.67	1.45	1.09	1.16	1.31	1.30	1.37
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	67	27	121	-89	5.47	-35	-38	45	79	-21	-18
Operating Cash Flow to CapEx	1,943.94%	1,857.55%	1,726.77%	1,200.77%	-201.16%	464.49%	-167.42%	2.05%	-1,118.27%	-226.88%	119.68%
Free Cash Flow to Firm to Interest Expense	19.69	9.39	39.47	-17.42	6.04	-40.33	-55.35	16.72	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	13.36	19.64	13.48	7.34	-16.05	27.98	-10.46	0.03	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	12.67	18.58	12.70	6.73	-24.02	21.96	-16.70	-1.38	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.47	0.38	0.37	0.35	0.37	0.50	0.57	0.62	0.71	0.98	1.17
Accounts Receivable Turnover	6.36	5.54	6.24	6.52	7.06	8.73	7.21	6.44	6.30	6.76	7.02
Inventory Turnover	2.93	2.29	2.51	2.89	2.28	2.47	3.01	3.08	2.57	2.20	2.54
Fixed Asset Turnover	6.89	5.77	7.38	10.83	10.05	8.90	7.71	7.58	7.59	8.61	10.78
Accounts Payable Turnover	9.29	7.47	6.96	5.94	5.43	6.93	6.31	4.80	3.82	3.79	4.48
Days Sales Outstanding (DSO)	57.39	65.88	58.54	55.96	51.71	41.81	50.62	56.64	57.91	53.97	51.99
Days Inventory Outstanding (DIO)	124.76	159.35	145.29	126.32	160.21	147.55	121.28	118.39	141.80	166.02	143.76
Days Payable Outstanding (DPO)	39.29	48.88	52.46	61.46	67.18	52.66	57.82	75.98	95.64	96.19	81.41
Cash Conversion Cycle (CCC)	142.86	176.35	151.36	120.82	144.73	136.71	114.08	99.04	104.07	123.81	114.35
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	607	572	441	524	401	411	429	348	134	127	117
Invested Capital Turnover	0.55	0.46	0.52	0.56	0.57	0.72	0.75	0.87	1.26	2.24	2.62
Increase / (Decrease) in Invested Capital	-66	-34	-131	82	-122	10	18	-81	-214	-7.18	-10
Enterprise Value (EV)	536	612	792	608	331	854	766	391	181	358	420
Market Capitalization	437	555	774	699	385	882	761	371	253	414	474
Book Value per Share	$13.95	$14.00	$14.74	$16.52	$12.07	$11.52	$10.95	$9.64	$5.13	$4.51	$4.13
Tangible Book Value per Share	($0.57)	$0.22	$3.92	$3.27	$1.52	$1.81	$1.83	$2.75	$3.20	$2.80	$2.51
Total Capital	641	621	636	751	456	459	458	443	210	183	171
Total Debt	133	106	94	137	0.84	20	34	65	4.73	0.00	0.00
Total Long-Term Debt	104	91	87	124	0.00	20	25	50	0.00	0.00	0.00
Net Debt	99	57	18	-91	-54	-28	4.96	20	-71	-56	-54
Capital Expenditures (CapEx)	2.33	3.00	2.39	3.12	7.24	5.19	4.30	3.81	2.52	4.46	2.58
Debt-free, Cash-free Net Working Capital (DFCFNWC)	75	48	42	26	48	35	49	50	31	36	35
Debt-free Net Working Capital (DFNWC)	109	97	118	254	102	83	78	94	107	92	89
Net Working Capital (NWC)	80	82	111	242	101	83	69	80	102	92	89
Net Nonoperating Expense (NNE)	44	-13	-26	-68	50	6.85	6.62	17	50	6.03	8.79
Net Nonoperating Obligations (NNO)	99	57	-101	-91	-54	-28	4.96	-30	-71	-56	-54
Total Depreciation and Amortization (D&A)	28	25	23	26	24	26	29	31	28	26	23
Debt-free, Cash-free Net Working Capital to Revenue	21.11%	17.89%	16.21%	9.79%	18.12%	12.07%	15.49%	14.72%	10.12%	12.39%	10.87%
Debt-free Net Working Capital to Revenue	30.71%	35.96%	45.03%	93.90%	38.73%	28.62%	24.60%	27.89%	35.15%	31.50%	27.70%
Net Working Capital to Revenue	22.47%	30.54%	42.32%	89.42%	38.41%	28.62%	21.83%	23.53%	33.59%	31.50%	27.70%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.21)	$0.14	$0.44	$1.64	($4.39)	($0.82)	($0.68)	($1.33)	($4.59)	($0.83)	($0.88)
Adjusted Weighted Average Basic Shares Outstanding	36.16M	36.62M	37.08M	37.48M	37.96M	38.34M	39.01M	39.48M	40.18M	40.85M	41.53M
Adjusted Diluted Earnings per Share	($1.21)	$0.14	$0.44	$1.64	($4.39)	($0.82)	($0.68)	($1.33)	($4.59)	($0.83)	($0.88)
Adjusted Weighted Average Diluted Shares Outstanding	36.16M	36.96M	37.54M	37.49M	37.96M	38.34M	39.01M	39.48M	40.18M	40.85M	41.53M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	36.44M	36.58M	36.89M	37.28M	37.87M	38.44M	38.97M	39.67M	40.28M	40.63M	41.33M
Normalized Net Operating Profit after Tax (NOPAT)	9.53	11	0.88	4.01	-1.75	-11	-14	-15	-24	-17	-16
Normalized NOPAT Margin	2.69%	4.24%	0.34%	1.48%	-0.66%	-3.62%	-4.30%	-4.34%	-7.89%	-5.82%	-4.88%
Pre Tax Income Margin	-0.92%	-5.30%	-6.60%	-5.43%	-63.65%	-12.39%	-9.47%	-16.07%	-63.06%	-11.64%	-11.34%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.04	-4.04	-4.64	-1.88	-184.37	-40.87	-42.53	-19.15	0.00	0.00	0.00
NOPAT to Interest Expense	0.21	-2.76	-3.24	-1.29	-128.96	-28.69	-28.97	-13.26	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-0.65	-5.09	-5.42	-2.49	-192.35	-46.90	-48.78	-20.56	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-0.48	-3.81	-4.02	-1.90	-136.94	-34.71	-35.21	-14.67	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	270.71%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4.91%	0.00%

This table displays calculated financial ratios and metrics derived from AngioDynamics' official financial filings.

Metric	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	Q4 2026
Period end date	11/30/2023	2/29/2024	5/31/2024	8/31/2024	11/30/2024	2/28/2025	5/31/2025	8/31/2025	11/30/2025	2/28/2026	5/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	40,606,986.00	40,633,885.00	41,199,844.00	41,217,386.00	41,318,915.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	40,606,986.00	40,633,885.00	41,199,844.00	41,217,386.00	41,318,915.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-0.15	-0.27	-0.15	-0.20	-0.28
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-7.44%	-6.85%	-22.06%	-14.22%	-7.88%	-4.23%	12.93%	12.18%	9.04%	8.91%	8.05%
EBITDA Growth	-1,077.96%	-17,570.83%	41.14%	-115.66%	34.76%	100.92%	96.45%	25.78%	88.01%	-234.82%	-1,804.64%
EBIT Growth	-57.19%	-2,141.64%	29.84%	-138.20%	15.74%	97.73%	58.44%	18.36%	43.58%	-75.70%	-78.80%
NOPAT Growth	-61.68%	-2,138.98%	30.66%	-119.89%	15.44%	95.01%	59.94%	18.64%	44.79%	-29.85%	-76.14%
Net Income Growth	-242.31%	-1,879.29%	37.35%	-127.89%	63.03%	97.65%	55.02%	14.81%	40.86%	-83.44%	-88.51%
EPS Growth	-242.86%	-1,845.83%	36.36%	-126.96%	63.89%	97.64%	57.14%	16.13%	42.31%	-72.73%	-86.67%
Operating Cash Flow Growth	-29.78%	-1,014.31%	-68.65%	29.52%	-53.04%	-5.05%	276.14%	12.81%	88.48%	76.37%	-7.22%
Free Cash Flow Firm Growth	488.72%	5,241.05%	207.28%	83.86%	159.42%	-102.43%	-98.47%	-100.53%	-100.66%	144.77%	-4.79%
Invested Capital Growth	-20.09%	-64.95%	-61.47%	-60.96%	-60.64%	-2.43%	-5.35%	-4.30%	-2.14%	-7.23%	-7.96%
Revenue Q/Q Growth	0.50%	-4.92%	-5.59%	-4.92%	7.93%	-1.15%	11.32%	-5.55%	4.92%	-1.27%	10.44%
EBITDA Q/Q Growth	-115.61%	-2,878.38%	95.90%	17.81%	34.95%	142.07%	-115.77%	-1,619.29%	89.49%	-372.92%	-122.86%
EBIT Q/Q Growth	-137.86%	-1,421.70%	92.65%	9.77%	16.49%	59.00%	-34.53%	-77.23%	42.28%	-27.68%	-36.90%
NOPAT Q/Q Growth	-119.92%	-1,423.60%	92.77%	9.35%	15.30%	10.10%	41.97%	-84.11%	42.52%	-111.44%	21.28%
Net Income Q/Q Growth	-163.31%	-546.30%	92.84%	4.84%	16.10%	58.96%	-37.28%	-80.21%	41.76%	-27.31%	-41.08%
EPS Q/Q Growth	-162.61%	-548.61%	92.51%	11.43%	16.13%	57.69%	-36.36%	-73.33%	42.31%	-26.67%	-47.37%
Operating Cash Flow Q/Q Growth	120.33%	-337.87%	139.93%	-464.99%	113.55%	-632.11%	242.95%	-184.60%	129.29%	-166.72%	661.16%
Free Cash Flow Firm Q/Q Growth	-34.00%	74.66%	48.36%	7.51%	-6.88%	-101.64%	193.56%	-137.43%	-14.71%	211.45%	98.99%
Invested Capital Q/Q Growth	-6.73%	-57.18%	-10.34%	9.03%	-5.97%	6.15%	-13.03%	10.24%	-3.85%	0.63%	-13.71%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	50.92%	47.70%	54.26%	54.41%	54.78%	53.97%	52.67%	55.29%	56.38%	52.89%	54.01%
EBITDA Margin	-8.18%	-256.19%	-11.12%	-9.61%	-5.79%	2.47%	-0.35%	-6.36%	-0.64%	-3.05%	-6.16%
Operating Margin	-16.59%	-265.88%	-20.36%	-19.41%	-15.23%	-13.85%	-7.22%	-14.07%	-7.71%	-16.51%	-11.77%
EBIT Margin	-16.63%	-266.20%	-20.72%	-19.66%	-15.21%	-6.31%	-7.63%	-14.31%	-7.87%	-10.18%	-12.62%
Profit (Net Income) Margin	-36.74%	-249.71%	-18.95%	-18.96%	-14.74%	-6.12%	-7.55%	-14.40%	-7.99%	-10.31%	-13.17%
Tax Burden Percent	230.21%	93.99%	95.11%	101.05%	98.99%	99.95%	99.02%	100.60%	99.92%	100.15%	103.35%
Interest Burden Percent	95.94%	99.80%	96.15%	95.43%	97.89%	97.03%	99.95%	100.04%	101.63%	101.10%	100.96%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-9.72%	-209.03%	-17.94%	-15.26%	-12.53%	-18.57%	-11.31%	-20.68%	-12.18%	-25.75%	-21.62%
ROIC Less NNEP Spread (ROIC-NNEP)	172.43%	33.79%	-11.35%	-8.21%	-6.63%	-23.31%	-8.17%	-12.94%	-7.64%	-28.28%	-13.84%
Return on Net Nonoperating Assets (RNNOA)	-4.65%	-2.16%	1.97%	1.36%	1.13%	6.26%	2.68%	3.07%	1.91%	6.11%	4.29%
Return on Equity (ROE)	-14.37%	-211.19%	-15.98%	-13.90%	-11.40%	-12.31%	-8.64%	-17.62%	-10.27%	-19.64%	-17.33%
Cash Return on Invested Capital (CROIC)	20.94%	47.94%	32.93%	23.08%	18.51%	-20.55%	-15.91%	-13.94%	-14.57%	-10.15%	-14.61%
Operating Return on Assets (OROA)	-10.36%	-198.81%	-14.81%	-14.62%	-11.02%	-5.86%	-7.46%	-15.39%	-8.62%	-11.70%	-14.77%
Return on Assets (ROA)	-22.89%	-186.49%	-13.54%	-14.10%	-10.68%	-5.68%	-7.39%	-15.49%	-8.75%	-11.84%	-15.41%
Return on Common Equity (ROCE)	-14.37%	-211.19%	-15.98%	-13.90%	-11.40%	-12.31%	-8.64%	-17.62%	-10.27%	-19.64%	-17.33%
Return on Equity Simple (ROE_SIMPLE)	-3.52%	-87.96%	0.00%	-123.63%	-120.32%	-22.27%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-9.18	-140	-10	-9.17	-7.77	-6.98	-4.05	-7.46	-4.29	-9.07	-7.14
NOPAT Margin	-11.61%	-186.12%	-14.25%	-13.58%	-10.66%	-9.70%	-5.05%	-9.85%	-5.40%	-11.56%	-8.24%
Net Nonoperating Expense Percent (NNEP)	-182.16%	-242.82%	-6.59%	-7.04%	-5.91%	4.74%	-3.14%	-7.74%	-4.54%	2.53%	-7.78%
Return On Investment Capital (ROIC_SIMPLE)	-2.24%	-61.32%	-	-	-4.05%	-3.66%	-2.21%	-4.17%	-2.43%	-5.23%	-4.18%
Cost of Revenue to Revenue	49.08%	52.30%	45.74%	45.59%	45.22%	46.03%	47.33%	44.71%	43.62%	47.11%	45.99%
SG&A Expenses to Revenue	11.75%	14.07%	14.71%	16.26%	14.26%	14.57%	12.77%	16.58%	12.78%	13.67%	11.85%
R&D to Revenue	10.95%	10.89%	9.47%	9.31%	8.83%	9.60%	8.22%	8.48%	9.78%	9.03%	9.44%
Operating Expenses to Revenue	67.51%	313.58%	74.62%	73.82%	70.01%	67.82%	59.89%	69.36%	64.09%	69.41%	65.78%
Earnings before Interest and Taxes (EBIT)	-13	-200	-15	-13	-11	-4.54	-6.11	-11	-6.25	-7.98	-11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.47	-193	-7.89	-6.49	-4.22	1.78	-0.28	-4.81	-0.51	-2.39	-5.33
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.65	1.00	1.23	1.53	1.51	2.02	2.26	2.33	2.90	2.72	2.78
Price to Tangible Book Value (P/TBV)	1.88	1.60	1.97	2.49	2.48	3.27	3.64	3.77	4.66	4.37	4.58
Price to Revenue (P/Rev)	0.79	0.68	0.83	1.03	0.98	1.33	1.42	1.39	1.66	1.50	1.48
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.60	1.00	1.35	1.71	1.69	2.30	2.82	2.70	3.48	3.20	3.60
Enterprise Value to Revenue (EV/Rev)	0.63	0.46	0.60	0.85	0.81	1.19	1.23	1.26	1.53	1.38	1.31
Enterprise Value to EBITDA (EV/EBITDA)	10.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	97.51	136.12
Enterprise Value to Free Cash Flow (EV/FCFF)	2.53	1.08	2.28	4.16	5.15	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.02	0.04	0.02	0.02	0.03	0.03	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.03	-0.06	-0.17	-0.17	-0.17	-0.27	-0.33	-0.24	-0.25	-0.22	-0.31
Leverage Ratio	1.31	1.41	1.46	1.26	1.35	1.51	1.54	1.49	1.55	1.52	1.55
Compound Leverage Factor	1.25	1.41	1.40	1.20	1.32	1.46	1.54	1.49	1.57	1.54	1.56
Debt to Total Capital	2.29%	4.16%	2.25%	2.39%	2.59%	2.62%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	2.29%	4.16%	2.25%	2.39%	2.59%	2.62%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	97.71%	95.84%	97.75%	97.61%	97.41%	97.38%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.46	-0.06	-0.03	-0.02	-0.02	-0.30	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-2.52	0.40	0.43	0.24	0.23	2.36	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-1.71	-0.07	-0.04	-0.03	-0.03	-0.15	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	9.37	0.50	0.53	0.30	0.29	1.17	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	1.87	-1.03	0.80	1.15	0.82	1.53	1.78	1.96	2.43	2.31	1.97
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.38	2.29	2.12	2.25	1.98	2.21	2.21	2.29	2.24	2.35	2.19
Quick Ratio	1.44	1.49	1.31	1.23	1.10	1.13	1.30	1.19	1.20	1.26	1.37
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	79	138	204	219	204	-3.34	3.13	-1.17	-1.34	1.50	2.98
Operating Cash Flow to CapEx	293.70%	-678.55%	0.00%	-758.96%	126.11%	-412.64%	0.00%	-1,026.05%	287.54%	-206.37%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.62	0.75	0.71	0.74	0.72	0.93	0.98	1.08	1.10	1.15	1.17
Accounts Receivable Turnover	6.31	6.46	6.30	6.55	6.05	6.10	6.76	7.32	7.02	7.05	7.02
Inventory Turnover	2.55	2.66	2.57	2.27	2.08	2.13	2.20	2.17	2.12	2.36	2.54
Fixed Asset Turnover	7.45	7.85	7.59	7.53	7.59	8.14	8.61	9.19	9.68	10.17	10.78
Accounts Payable Turnover	4.49	4.56	3.82	5.04	3.74	3.95	3.79	4.37	3.98	4.83	4.48
Days Sales Outstanding (DSO)	57.85	56.53	57.91	55.69	60.36	59.87	53.97	49.89	52.02	51.78	51.99
Days Inventory Outstanding (DIO)	143.24	137.44	141.80	160.95	175.33	171.01	166.02	168.04	171.90	154.87	143.76
Days Payable Outstanding (DPO)	81.31	79.97	95.64	72.40	97.51	92.32	96.19	83.59	91.70	75.56	81.41
Cash Conversion Cycle (CCC)	119.78	114.00	104.07	144.24	138.18	138.55	123.81	134.34	132.23	131.09	114.35
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	350	150	134	146	138	146	127	140	135	136	117
Invested Capital Turnover	0.84	1.12	1.26	1.12	1.18	1.92	2.24	2.10	2.26	2.23	2.62
Increase / (Decrease) in Invested Capital	-88	-277	-214	-229	-212	-3.64	-7.18	-6.29	-2.94	-11	-10
Enterprise Value (EV)	209	150	181	250	232	336	358	378	469	434	420
Market Capitalization	260	219	253	300	282	376	414	417	511	472	474
Book Value per Share	$10.07	$5.49	$5.13	$4.88	$4.60	$4.59	$4.51	$4.40	$4.28	$4.21	$4.13
Tangible Book Value per Share	$3.47	$3.44	$3.20	$3.00	$2.80	$2.84	$2.80	$2.72	$2.66	$2.62	$2.51
Total Capital	411	228	210	201	192	191	183	179	176	173	171
Total Debt	9.39	9.50	4.73	4.80	4.96	5.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-52	-69	-71	-50	-49	-40	-56	-39	-42	-38	-54
Capital Expenditures (CapEx)	1.79	1.85	-2.68	2.41	1.96	3.19	-3.09	1.55	1.62	1.51	-2.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	56	42	31	46	38	55	36	50	48	52	35
Debt-free Net Working Capital (DFNWC)	117	121	107	101	92	99	92	88	89	89	89
Net Working Capital (NWC)	107	111	102	96	87	94	92	88	89	89	89
Net Nonoperating Expense (NNE)	20	48	3.33	3.63	2.97	-2.57	2.00	3.44	2.06	-0.98	4.27
Net Nonoperating Obligations (NNO)	-52	-69	-71	-50	-49	-40	-56	-39	-42	-38	-54
Total Depreciation and Amortization (D&A)	6.69	7.52	6.82	6.79	6.86	6.32	5.83	6.02	5.75	5.59	5.60
Debt-free, Cash-free Net Working Capital to Revenue	16.97%	12.99%	10.12%	15.61%	13.14%	19.25%	12.39%	16.50%	15.54%	16.47%	10.87%
Debt-free Net Working Capital to Revenue	35.45%	37.20%	35.15%	34.40%	32.02%	35.05%	31.50%	29.39%	29.09%	28.52%	27.70%
Net Working Capital to Revenue	32.60%	34.27%	33.59%	32.76%	30.28%	33.28%	31.50%	29.39%	29.09%	28.52%	27.70%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.72)	($4.67)	($0.35)	($0.31)	($0.26)	($0.11)	($0.15)	($0.26)	($0.15)	($0.19)	($0.28)
Adjusted Weighted Average Basic Shares Outstanding	40.22M	40.23M	40.18M	40.65M	40.92M	40.85M	40.85M	41.17M	41.54M	41.60M	41.53M
Adjusted Diluted Earnings per Share	($0.72)	($4.67)	($0.35)	($0.31)	($0.26)	($0.11)	($0.15)	($0.26)	($0.15)	($0.19)	($0.28)
Adjusted Weighted Average Diluted Shares Outstanding	40.22M	40.23M	40.18M	40.65M	40.92M	40.85M	40.85M	41.17M	41.54M	41.60M	41.53M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	39.86M	40.05M	40.28M	40.63M	40.47M	40.61M	40.63M	41.20M	41.22M	41.32M	41.33M
Normalized Net Operating Profit after Tax (NOPAT)	-4.85	-8.20	-4.22	-6.15	-3.66	-4.68	-2.54	-5.53	-1.74	-4.50	-3.86
Normalized NOPAT Margin	-6.14%	-10.90%	-5.95%	-9.11%	-5.02%	-6.50%	-3.17%	-7.30%	-2.19%	-5.74%	-4.46%
Pre Tax Income Margin	-15.96%	-265.68%	-19.92%	-18.77%	-14.89%	-6.12%	-7.62%	-14.32%	-8.00%	-10.29%	-12.74%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4.91%	-3.48%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

AngioDynamics (NASDAQ: ANGO) is showing a mixed but improving operating picture in its latest quarter, with revenue growth and strong operating cash flow offset by continued losses and heavy restructuring-related expenses.

For the fiscal fourth quarter of 2026, revenue rose to $86.6 million from $80.2 million in the prior-year quarter, while gross profit increased to $46.8 million. Despite that top-line improvement, the company still posted a net loss of $11.4 million, or $(0.28) per share, mainly because operating expenses remained very high.

One encouraging sign is cash generation. AngioDynamics produced $17.5 million in operating cash flow in Q4 2026, a sharp improvement from the $3.1 million outflow in Q3 2026 and the $5.0 million inflow in Q4 2025. The company ended Q4 2026 with $16.1 million of net cash added during the quarter.

That said, the broader trend over the last several quarters still points to an unprofitable business that has relied on significant expense actions and occasional balance sheet support. Restructuring charges have been a recurring feature, and the company also recorded a major impairment charge in Q3 2024, which highlights the strain in parts of the business.

Revenue growth resumed in Q4 2026, with sales rising year over year to $86.6 million from $80.2 million.
Gross profit improved meaningfully, reaching $46.8 million in Q4 2026 versus $42.2 million in Q4 2025.
Operating cash flow was strong in the latest quarter, generating $17.5 million from operations.
Cash and equivalents improved sequentially in Q4 2026, supported by the positive net change in cash.
Shares outstanding have been relatively stable around 41.5 million in recent quarters, suggesting limited dilution pressure lately.
Balance sheet leverage appears manageable in the latest quarter, with total liabilities of $87.3 million against $173.4 million of equity at Q3 2026.
Working capital remains sizable, supported by current assets of $155.6 million at Q3 2026.
The company remains unprofitable, posting a Q4 2026 net loss of $11.4 million and losses in each of the last several quarters.
Operating expenses are still very heavy, with Q4 2026 operating expenses of $57.0 million exceeding gross profit.
Restructuring and special charges remain a recurring issue, contributing to volatility in earnings and signaling ongoing business restructuring.

Longer-term trend: AngioDynamics has made progress on cash generation and revenue stabilization, but profitability remains elusive. Over the past four years, revenue has generally ranged in the low-to-mid $70 million to low-$90 million quarterly range, while earnings have swung from occasional large gains to substantial losses. The company’s latest results suggest operational momentum is better than it was a year ago, but investors should still view ANGO as a turnaround story rather than a consistently profitable medical device business.

07/26/26 02:20 AM ETAI Generated. May Contain Errors.

AngioDynamics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, AngioDynamics' financial year ends in May. Their financial year 2026 ended on May 31, 2026.

AngioDynamics' net income appears to be on an upward trend, with a most recent value of -$36.74 million in 2026, falling from -$43.59 million in 2016. The previous period was -$33.99 million in 2025. See AngioDynamics' forecast for analyst expectations on what's next for the company.

AngioDynamics' total operating income in 2026 was -$39.93 million, based on the following breakdown:

Total Gross Profit: $174.89 million
Total Operating Expenses: $214.82 million

Over the last 10 years, AngioDynamics' total revenue changed from $353.89 million in 2016 to $320.17 million in 2026, a change of -9.5%.

AngioDynamics' total liabilities were at $96.34 million at the end of 2026, a 0.9% decrease from 2025, and a 56.0% decrease since 2016.

In the past 10 years, AngioDynamics' cash and equivalents has ranged from $28.83 million in 2022 to $227.64 million in 2019, and is currently $53.86 million as of their latest financial filing in 2026.

Over the last 10 years, AngioDynamics' book value per share changed from 13.95 in 2016 to 4.13 in 2026, a change of -70.4%.

Related Companies

Financial statements for NASDAQ:ANGO last updated on 7/19/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AngioDynamics (ANGO) Financials

Financials Breakdown Chart

Key Financial Trends

AngioDynamics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AngioDynamics (ANGO) Financials

Annual Income Statements for AngioDynamics

Quarterly Income Statements for AngioDynamics

Annual Cash Flow Statements for AngioDynamics

Quarterly Cash Flow Statements for AngioDynamics

Annual Balance Sheets for AngioDynamics

Quarterly Balance Sheets for AngioDynamics

Annual Metrics And Ratios for AngioDynamics

Quarterly Metrics And Ratios for AngioDynamics

Financials Breakdown Chart

Key Financial Trends

AngioDynamics Financials - Frequently Asked Questions

When does AngioDynamics' fiscal year end?

How has AngioDynamics' net income changed over the last 10 years?

What is AngioDynamics' operating income?

How has AngioDynamics' revenue changed over the last 10 years?

How much debt does AngioDynamics have?

How much cash does AngioDynamics have?

How has AngioDynamics' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools